Advances in allergy management

Allergy: European Journal of Allergy and Clinical Immunology, Supplement

Volumn 57, Issue 75, 2002, Pages 29-36

  Van Cauwenberge, Paul ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Allergic rhinitis; Asthma; Desloratadine; Pathophysiology; Pharmacoeconomics

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALTRAKINCEPT; DESLORATADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; MEPOLIZUMAB; MONOCLONAL ANTIBODY; MONTELUKAST; NOLPITANTIUM; OMALIZUMAB; SAREDUTANT; ZAFIRLUKAST;

ALLERGY; ARTICLE; DRUG EFFICACY; DRUG INDICATION; EPIDEMIOLOGICAL DATA; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

HISTAMINE H1 ANTAGONISTS; HUMANS; INFLAMMATION MEDIATORS; LORATADINE; NASAL OBSTRUCTION; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0036967396     PISSN: 01081675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. KAY AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001;344:30-37.
2. CANONICA GW. Introduction to the nasal and pulmonary allergy cascade. Allergy 2002;57(Suppl. 75):8-12.
3. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl.):S147-S334.
4. SEKIYA T, YAMADA H, YAMAGUCHI M et al. Increased levels of TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 2002;57:173-177.
5. TERADA N, NOMURA T, KIM WJ et al. Expression of C-C chemokine TARC in human nasal mucosa and its regulation by cytokines. Clin Exp Allergy 2001;31:1809-1812.
6. KANWAR S, JOHNSTON B, KUBES P. Leukotriene C4/D4 induces P-selectin and sialyl Lewis (x)-dependent alterations in leukocyte kinetics in vivo. Circ Res 1995;77:879-887.
7. STRACHAN D, SIBBALD B, WEILAND S et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8:161-176.
8. CIPRANDI G, VIZZACCARO A, CIRILLO I, CRIMI P, CANONICA G. Increase of asthma and allergic rhinitis prevalence in young Italian men. Int Arch Allergy Immunol 1996;111:279-283.
9. ABERG N, HESSELMAR B, ABERG B, ERIKSSON B. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. Clin Exp Allergy 1995;25:815-819.
10. EVANS R III, MULLALLY DI, WILSON RW et al. National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization and death from asthma over two decades: 1965-1984. Chest 1987;91:65S-74S.
11. ABERG N. Asthma and allergic rhinitis in Swedish conscripts. Clin Exp Allergy 1989;19:59-63.
12. BRODER I, HIGGINS MW, MATHEWS KP, KELLER JB. Epidemiology of asthma and allergic rhinitis in a total community, Tecumseh, Michigan. IV. Natural history. J Allergy Clin Immunol 1974;54:100-110.
13. SETTIPANE G, SETTIPANE RJ, HAGY GW. Long term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994;15:21-25.
14. ANDERSON HR, POTTIER AC, STRACHAN DP. Asthma from birth to age 23: incidence and relationship to prior and concurrent atopic status. Thorax 1992;47:537-542.
15. JENKINS MA, HOPPER JL, FLANDER LB et al. The associations between childhood asthma, and atopy, and parental asthma, hay fever and smoking. Paediatr Perinat Epidemiol 1993;7:67-76.
16. LOMBARDI C, PASSALACQUA G, GARGIONI S et al. The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years. Respir Med 2001;95:9-12.
17. CORREN J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997;99:S781-S786.
18. BALL TM, CASTRO-RODRIGUEZ JA, GRIFFITH KA, HOLBERG CJ, MARTINEZ FD, WRIGHT AL. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med 2000;343:538-543.
19. OPENSHAW PJ, HEWITT C. Protective and harmful effects of viral infections in childhood on wheezing disorders and asthma. Am J Respir Crit Care Med 2000;162(2:2):S40-S43.
20. KARMAUS W, BOTEZAN C. Does a higher number of siblings protect against the development of allergy and asthma? A review. J Epidemiol Community Health 2002;56:209-217.
21. COOKSON W. The alliance of genes and environment in asthma and allergy. Nature 1999;402(Suppl. 6760):B5-B11.
22. WARNER JA, JONES AC, MILES EA, COLWELL BM, WARNER JO. Prenatal origins of asthma and allergy. Ciba Found Symp 1997;206:220-228, 228-232(discussion).
23. ERIKSSON NE, HOLMEN A. Skin prick tests with standardized extracts of inhalant allergens in 7099 adult patients with asthma or rhinitis. Cross-sensitizations and relationships to age, sex, month of birth and year of testing. J Invest Allergol Clin Immunol 1996;6:36-46.
24. QUOIX E, BESSOT JC, KOPFERSCHMITT-KUBLER MC, FRAISSE P, PAULI G. Positive skin tests to aero-allergens and month of birth. Allergy 1988;43:127-131.
25. COOKSON WO. Asthma genetics. Chest 2002;121(Suppl. 3):7S-13S.
26. TODA M, ONO SJ. Genomics and proteomics of allergic disease. Immunology 2002;106:1-10.
27. MARSH DG, HSU SH, ROEBBER M et al. HLA-Dw2: a genetic marker for human immune response to short ragweed pollen allergen Ra5. I. Response resulting primarily from natural antigenic exposure. J Exp Med, 1982;155:1439-1451.
28. HILL MR, COOKSON WO. A new variant of the beta subunit of the high-affinity receptor for immunoglobulin E (Fc epsilon RI-beta E237G): associations with measures of atopy and bronchial hyper-responsiveness. Hum Mol Genet 1996;5:959-962.
29. MARSH DG, NELLY JD, BREAZEALE DR et al. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 1994;264:1152-1156.
30. BALDINI M, LOHMAN IC, HALONEN M, ERICKSON RP, HOLT PG, MARTINEZ FD. A polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999;20:976-983.
31. GREEN RM, CUSTOVIC A, SANDERSON G, HUNTER J, JOHNSTON SL, WOODCOCK A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 2002;324:763.
32. SALVI S. Pollution and allergic airways disease. Curr Opin Allergy Clin Immunol 2001;1:35-41.
33. LODRUP CARLSEN KC, CARLSEN KH. Effects of maternal and early tobacco exposure on the development of asthma and airway hyperreactivity. Curr Opin Allergy Clin Immunol 2001;1:139-143.
34. PIEDIMONTE G. The association between respiratory syncytial virus infection and reactive airway disease. Respir Med 2002;96(Suppl. B):S25-S29.
35. FINEMAN SM. The burden of allergic rhinitis, beyond dollars and cents. Ann Allergy Asthma Immunol 2002;88(Suppl. 1):2-7.
36. DESSI P, ALLAERT FA, URBINELLI R, VERRIERE JL. Medico-economic aspects of the management of perennial allergic rhinitis in general medicine. Allerg Immunol (Paris) 1998;30:277-283.
37. KESSLER RC, ALMEIDA DM, BERGLUND P, STANG P. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:289-295.
38. CRYSTAL-PETERS J, CROWN WH, GOETZEL RZ, SCHUTT DC. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000;6:373-378.
39. CUFFEL B, WAMBOLDT M, BORISH L, KENNEDY S, CRYSTAL-PETERS J. Economic consequences of comorbid depression, anxiety, and allergic rhinitis. Psychosomatics 1999;40:491-496.
40. SZUCS TD, ANDERHUB H, RUTISHAUSER M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J 1999;13:281-286.
41. WEISSFLOG D, MATTHYS H, VIRCHOW JC JR. Epidemiology and costs of bronchial asthma and chronic bronchitis in Germany. Dtsch Med Wochenschr 2001;126:803-808.
42. WEISS KB, SULLIVAN SD, LYTTLE CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol 2000;106:493-499.
43. NOWAK D, VOLMER T, WETTENGEL R. Bronchial asthma - a cost of illness analysis. Pneumologie 1996;50:364-371.
44. SMITH C. A national estimates of the economic costs of asthma. Am J Respir Crit Care Med 1997;156:797-793.
45. GALLEFOSS F, BAKKE PS. Cost-effectiveness of self-management in asthmatics: a 1-yr follow-up randomized, controlled trial. Eur Respir J 2001;17:206-213.
46. SERRA-BATLLES J, PLAZA V, MOREJON E, COMELLA A, BRUGUES J. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322-1326.
47. SZUCS TD, ANDERHUB HP, RUTISHAUSER M. Determinants of health care costs and patterns of care of asthmatic patients in Switzerland. Schweiz Med Wochenschr 2000;130:305-313.
48. GRAF VON DER SCHULENBURG JM, GREINER W, MOLITOR S, KIELHORN A. Cost of asthma therapy in relation to severity. An empirical study. Med Klin 1996;91:670-676.
49. PLAZA V, SERRA-BATLLES J, FERRER M, MOREJON E. Quality of life and economic features in elderly asthmatics. Respiration 2000;67:65-70.
50. UNGAR WJ, COYTE PC. Measuring productivity loss days in asthma patients. The Pharmacy Medicaton Monitoring Program Advisory Board. Health Econ 2000;9:37-46.
51. MELTZER EO. Pharmacological treatment options for allergic rhinitis and asthma. Clin Exp Allergy 1998;28(Suppl. 2):27-36.
52. BARNES PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999;104:S10-S17.
53. TORPHY TJ. Action of mediators on airway smooth muscle: functional antagonism as a mechanism for bronchodilator drugs. Agents Actions Suppl 1988;23:37-53.
54. JOHNSON DA, HRICIK JG. The pharmacology of alpha-adrenergic decongestants. Pharmacotherapy 1993;13:110S-115S, 143S-146S(discussion).
55. BOUMPAS DT, CHROUSOS GP, WILDER RL, CUPPS TR, BALOW JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119:1198-1208.
56. 1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992;262:964-970.
57. BACHERT C. Therapeutic points of intervention and clinical implications: role of desloratadine. Allergy 2002;57(Suppl. 75): 13-18.
58. HUGER M, TRAIDL-HOFFMANN C, KASCHE A, RING J, BEHRENDT H. Influence of desloratadine on the chemotactic activity of human polymorphonuclear leukocytes. Allergy 2002;57(Suppl. 73):38.
59. MARSHALL G, HENNINGER E, MANIATIS E, RITTER S, SALICRU A, MESSICK C. Immunomodulatory effects of desloratadine: changes in type-1/type-2 cytokine expression in PBMC cultures. J Allergy Clin Immunol 2002;109(Suppl.):S206-S207.
60. RING J, HEIN R, GAUGER A, BRONSKY E, MILLER B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40:72-76.
61. 1-receptor antagonist, in patients with seasonal allergic rhinitis assessment during the spring and fall allergy season. Clin Drug Invest 2001;21:25-32.
62. DUBUSKE L. Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks. J Allergy Clin Immunol 2001;107:S159.
63. BAENA-CAGNANI C. Desloratadine improved asthma symptoms and decreased beta 2-agonist use in patients with seasonal allergic rhinitis and concomitant asthma. Allergy 2001;56(Suppl. 68):22.
64. BACHERT C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56(Suppl. 65):14-20.
65. GEHA RS, MELTZER EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751-762.
66. HORAK F, STÜBNER P, ZIEGLMAYER R, MOSER M, KAWINA A, ENGELBRECHT W. Decongestant activity of desloratadine versus placebo in allergic rhinitis: results from 3 single-dose, placebo-controlled, allergen chamber trials. Allergy 2001;56(Suppl. 68):79.
67. HORAK F, STÜBNER P, ZIEGLMAYER R, HARRIS AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109:956-961.
68. DALY A. Desloratadine reduces nasal congestion in SAR with greater magnitude than fexofenadine, cetrizine and loratadine. Allergy 2001;56(Suppl. 68):79.
69. RING J, HEIN R, GAUGER A, BRONSKY E, MILLER B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40:72-76.
70. Data on file. Schering-Plough, 2002.